{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:40:01Z","timestamp":1792730401224,"version":"4.5.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The treatment of immune thrombocytopenia (ITP) is a major clinical challenge and has a significant impact on health-related quality of life (HRQoL), and prolonged use of corticosteroids may have a negative impact on HRQoL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the impact of ITP on HRQoL and complications of corticosteroid treatment in patients with ITP in two teaching hospitals in Ethiopia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The institution-based cross-sectional study was conducted from November 15, 2022, to March 15, 2023, to recruit 214 study participants during the study period (4\u2009months). The ITP Life Quality Index (ILQI) in the Amharic version was used to assess the impact of ITP. Linear regression analysis models were also used, and a <jats:italic>p<\/jats:italic>-value of less than 0.05 was generally considered statistically significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Regarding treatment, the majority 172 (80.4%) of study participants were taking prednisolone only, and 143 (66.8%) of study participants had at least one side effect of corticosteroids during the entire treatment period. Predictive factors for a higher impact of ITP on HRQoL; all correlated variables explained 36.5% (adjusted R-squared\u2009=\u20090.365, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.0001) of the variance and had a moderate impact on HRQoL. Furthermore, predictive factors for an increasingly higher impact of ITP on HRQoL were the development of emotionally related corticosteroid side effects (<jats:italic>\u03b2<\/jats:italic>\u2009=\u20090.392, 95% CI: 5.160\u20139.961, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), the presence of fatigue during the assessment (<jats:italic>\u03b2<\/jats:italic>\u2009=\u20090.326, 95% CI: 4.394\u20139.475, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), patients not taking cotrimoxazole prophylaxis treatment (<jats:italic>\u03b2<\/jats:italic>\u2009=\u20090.236, 95% CI: 2.236\u20136.570, p\u2009&amp;lt;\u20090.001), living far from the hematology clinic (outside Addis Ababa) (<jats:italic>\u03b2<\/jats:italic>\u2009=\u20090166, 95% CI: 1.107\u20135.114 <jats:italic>p<\/jats:italic>\u2009=\u20090.003), having epistaxis and\/or wet purpura (mucosal bleeding) (<jats:italic>\u03b2<\/jats:italic>\u2009=\u20090.191, 95% CI: 0.091\u20134.259, <jats:italic>p<\/jats:italic>\u2009=\u20090.001), and skin symptoms (petechiae and ecchymosis) (<jats:italic>\u03b2<\/jats:italic>\u2009=\u20090.041, 95% CI: 0.091\u20134.259 <jats:italic>p<\/jats:italic>\u2009=\u20090.041) during diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The impact of ITP on their energy levels and work life was high compared to the impact of ITP on daily life. The side effects of corticosteroids also affect the HRQoL of ITP patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1423161","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T04:31:47Z","timestamp":1730781107000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Health-related quality of life and complications of corticosteroid treatment in patients with immune thrombocytopenia in two teaching hospitals in Ethiopia: a cross-sectional study"],"prefix":"10.3389","volume":"11","author":[{"given":"Dessale Abate","family":"Beyene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eskinder Ayalew","family":"Sisay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atalay Mulu","family":"Fentie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amha","family":"Gebremedhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1182\/blood-2019-131725","article-title":"Autoantibody-mediated desialylation impairs human thrombopoiesis and platelet lifespan","volume":"134","author":"Marini","year":"2019","journal-title":"Haematologica"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4236\/jbm.2018.69002","article-title":"Value of pre-and post-treatment platelet indices in patients with immune thrombocytopenic Purpura","volume":"6","author":"Omar","year":"2018","journal-title":"J Biosci Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/MOH.0b013e32833e7561","article-title":"Novel clearance mechanisms of platelets","volume":"17","author":"Grozovsky","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.htct.2017.11.001","article-title":"Guideline on immune thrombocytopenia in adults: associa\u00e7\u00e3o Brasileira de hematologia, hemoterapia e terapia celular. Project guidelines: associa\u00e7\u00e3o m\u00e9dica Brasileira\u20132018","volume":"40","author":"Ozelo","year":"2018","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/ajh.26045","article-title":"Immune thrombocytopenia (ITP) world impact survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment","volume":"96","author":"Cooper","year":"2021","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3109\/09537104.2013.831065","article-title":"Health-related quality of life in adult patients with chronic immune thrombocytopenia in Serbia","volume":"25","author":"Suvajdzic","year":"2014","journal-title":"Platelets"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/ajh.24463","article-title":"Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease","volume":"91","author":"Efficace","year":"2016","journal-title":"Am J Hematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/ajh.20992","article-title":"Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura","volume":"83","author":"McMillan","year":"2008","journal-title":"Am J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1185\/03007990802377461","article-title":"Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey","volume":"24","author":"Snyder","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/bjh.13415","article-title":"Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012","volume":"170","author":"Michel","year":"2015","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/17474086.2018.1548930","article-title":"Health-related quality of life in adult primary immune thrombocytopenia","volume":"11","author":"Sest\u00f8l","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/medicina55040112","article-title":"Prognostic factors for immune thrombocytopenic purpura remission after laparoscopic splenectomy: a cohort study","volume":"55","author":"Kwiatkowska","year":"2019","journal-title":"Medicina"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/S2352-3026(15)00003-4","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"2","author":"Chugh","year":"2015","journal-title":"Lancet Haematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/1316096","article-title":"Efficacy and safety of the combination treatment of rituximab and dexamethasone for adults with primary immune thrombocytopenia (ITP): a meta-analysis","volume":"2018","author":"Wang","year":"2018","journal-title":"Biomed Res Int"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/PROM.S140932","article-title":"Immune thrombocytopenia: improving quality of life and patient outcomes","volume":"9","author":"Trotter","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/archdischild-2013-303784","article-title":"Quality of life in immune thrombocytopenia following treatment","volume":"98","author":"Grainger","year":"2013","journal-title":"Arch Dis Child"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21037\/ales-19-260","article-title":"Idiopathic thrombocytopenic purpura: current therapeutical strategies and review of the literature on outcome after splenectomy","volume":"7","author":"Vecchio","year":"2020","journal-title":"Ann Laparosc Endosc Surg"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e017902","DOI":"10.1136\/bmjopen-2017-017902","article-title":"International variations in primary care physician consultation time: a systematic review of 67 countries","volume":"7","author":"Irving","year":"2017","journal-title":"BMJ Open"},{"key":"ref22","volume-title":"World health statistics","year":"2020"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3390\/medicina56120667","article-title":"Immune thrombocytopenia (ITP): current limitations in patient management","volume":"56","author":"Terrell","year":"2020","journal-title":"Medicina"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1600-0609.2009.01265.x","article-title":"Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives","volume":"83","author":"Guidry","year":"2009","journal-title":"Eur J Haematol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2326-12-2","article-title":"Patient-reported treatment burden of chronic immune thrombocytopenia therapies","volume":"12","author":"Brown","year":"2012","journal-title":"BMC Blood Disord"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7525-6-13","article-title":"Impact of chronic immune thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective","volume":"6","author":"Mathias","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1600-0609.2007.00844.x","article-title":"Health-related quality of life measured by the short form 36 in immune thrombocytopenic purpura: a cross-sectional survey in China","volume":"78","author":"Zhou","year":"2007","journal-title":"Eur J Haematol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2141.2008.07464.x","article-title":"Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials","volume":"144","author":"George","year":"2009","journal-title":"Br J Haematol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1185\/03007990802634119","article-title":"Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences","volume":"25","author":"Mathias","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.1007\/s12325-021-01934-0","article-title":"Psychometric evaluation of ITP life quality index (ILQI) in a global survey of patients with immune thrombocytopenia","volume":"38","author":"Viana","year":"2021","journal-title":"Adv Ther"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"20503121231199869","DOI":"10.1177\/20503121231199869","article-title":"Reliability and validity of the Amharic version of immune thrombocytopenia life quality index tool for assessment of the health-related quality of life in Ethiopian patients of immune thrombocytopenia: cross-sectional study","volume":"11","author":"Beyene","year":"2023","journal-title":"SAGE Open Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492187","article-title":"Immune thrombocytopenia-current diagnostics and therapy: recommendations of a joint working group of DGHO, \u00d6GHO, SGH, GPOH, and DGTI","volume":"41","author":"Matzdorff","year":"2018","journal-title":"Oncol Res Treat"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ajh.26036","article-title":"Immune thrombocytopenia (ITP) world impact survey (I-WISh): impact of ITP on health-related quality of life","volume":"96","author":"Cooper","year":"2021","journal-title":"Am J Hematol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s00277-020-04257-2","article-title":"Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center","volume":"99","author":"Jaime-P\u00e9rez","year":"2020","journal-title":"Ann Hematol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10245332.2017.1311442","article-title":"Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study","volume":"22","author":"Palau","year":"2017","journal-title":"Hematology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3324\/haematol.2016.146373","article-title":"Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome","volume":"101","author":"Grimaldi-Bensouda","year":"2016","journal-title":"Haematologica"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s00277-002-0488-x","article-title":"Overview of 321 patients with idiopathic thrombocytopenic purpura: retrospective analysis of the clinical features and response to therapy","volume":"81","author":"Pamuk","year":"2002","journal-title":"Ann Hematol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e0267342","DOI":"10.1371\/journal.pone.0267342","article-title":"Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: results from a questionnaire conducted in Switzerland, Austria, and Belgium","volume":"17","author":"Rov\u00f3","year":"2022","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12288-019-01124-7","article-title":"Health-related quality of life and burden of fatigue in Chinese patients with immune thrombocytopenia: a cross-sectional study","volume":"36","author":"Yang","year":"2020","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-022-00429-y","article-title":"How do patients and physicians perceive immune thrombocytopenia (ITP) as a disease? Results from Indian analysis of ITP world impact survey (I-WISh)","volume":"6","author":"Chakrabarti","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/bjh.17694","article-title":"Qualitative study to support the content validity of the immune thrombocytopenia (ITP) life quality index (ILQI)","volume":"194","author":"Cooper","year":"2021","journal-title":"Br J Haematol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/bjh.16751","article-title":"Fatigue in children and adolescents with immune thrombocytopenia","volume":"191","author":"Grace","year":"2020","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1423161\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T04:31:52Z","timestamp":1730781112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1423161\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":43,"alternative-id":["10.3389\/fmed.2024.1423161"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1423161","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"article-number":"1423161"}}